OKYO Pharma (NASDAQ:OKYO) Raised to "Strong-Buy" at Piper Sandler

OKYO Pharma (NASDAQ:OKYO - Get Free Report) was upgraded by analysts at Piper Sandler to a "strong-buy" rating in a research note issued to investors on Friday,Zacks.com reports.Several other equities research analysts have also recently commented on OKYO. HC Wainwright reaffirmed a "buy" rating and set a $7.00 target price on shares of OKYO Pharma in a research note on Thursday, January 29th. Weiss Ratings restated a "sell (d-)" rating on shares of OKYO Pharma in a report on Thursday, January 22nd. Finally, B. Riley Financial started coverage on shares of OKYO Pharma in a research note on Monday, December 8th. They issued a "buy" rating and a $5.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, OKYO Pharma currently has a consensus rating of "Moderate Buy" and a consensus target price of $6.33.Get Our Latest Stock Report on OKYO PharmaOKYO Pharma Trading Down 3.4%OKYO opened at $1.70 on Friday. OKYO Pharma has a twelve month low of $1.03 and a twelve month high of $3.35. The company has a fifty day moving average of $2.11 and a 200-day moving average of $2.23. OKYO Pharma (NASDAQ:OKYO - Get Free Report) last issued its quarterly earnings results on Friday, January 30th. The company reported ($2.28) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by ($2.21). As a group, analysts forecast that OKYO Pharma will post -0.17 EPS for the current year. Institutional Investors Weigh In On OKYO PharmaSeveral hedge funds and other institutional investors have recently modified their holdings of OKYO. Citadel Advisors LLC acquired a new position in shares of OKYO Pharma during the third quarter worth approximately $31,000. Renaissance Technologies LLC increased its stake in OKYO Pharma by 235.0% during the 4th quarter. Renaissance Technologies LLC now owns 138,000 shares of the company's stock valued at $286,000 after purchasing an additional 96,800 shares in the last quarter. Finally, XTX Topco Ltd acquired a new position in OKYO Pharma during the fourth quarter worth $36,000. Institutional investors own 2.97% of the company's stock. OKYO Pharma Company Profile (Get Free Report)Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company's pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis. Okyo Pharma's lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.Read MoreFive stocks we like better than OKYO PharmaThe gold chart Wall Street is terrified of…Buy this Gold Stock Before May 2026What a Former CIA Agent Knows About the Coming CollapseThis $15 Stock Could Go Down as the #1 Stock of 2026New gold price targetThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in OKYO Pharma Right Now?Before you consider OKYO Pharma, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OKYO Pharma wasn't on the list.While OKYO Pharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here